Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intra-Cellular Therapies Inc. - Common Stock (NQ:ITCI)

131.87 UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intra-Cellular Therapies Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Nasdaq, S&P 500 Fall As Bond Yields Pressure Tech Stocks ↗
Stocks are a mixed bag to start the week. 
Via Talk Markets
Topics Stocks Stocks / Equities
News headline image
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge ↗
 
Via Benzinga
News headline image
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal ↗
Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies boosts its CNS portfolio with Caplyta and a promising clinical-stage pipeline. 
Via Benzinga
News headline image
Demystifying Intra-Cellular Therapies: Insights From 15 Analyst Reviews ↗
 
Via Benzinga
News headline image
Earnings Preview For Intra-Cellular Therapies ↗
 
Via Benzinga
News headline image
Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (12 Ratings) ↗
 
Via Benzinga
News headline image
Expert Ratings For Intra-Cellular Therapies ↗
 
Via Benzinga
News headline image
Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal ↗
The deal values the smaller biotech company at a 39% premium to last week's closing price. 
Via Investor's Business Daily
News headline image
ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-Cellular Therapies, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Intra-Cellular Therapies Stock Shines Amid Market Slump On J&J’s $14.6B Buyout Deal: Retail Brims With Optimism ↗
ITCI's flagship product, Caplyta, is a once-daily oral therapy approved for treating schizophrenia and depressive episodes linked to bipolar disorders, which reportedly raked in sales of $464 million... 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
From Johnson & Johnson
Via Business Wire
News headline image
Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (9 Ratings) ↗
 
Via Benzinga
News headline image
A Closer Look at 11 Analyst Recommendations For Intra-Cellular Therapies ↗
 
Via Benzinga
News headline image
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Walgreens Boots Alliance, Aurora Innovation And Delta Air Lines Are Among Top Large Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio? ↗
Top performers in last week's stock market: Walgreens, Constellation Energy, FTAI Aviation, TD SYNNEX, Aurora Innovation, Royalty Pharma, Micron, Delta Air Lines, Intra-Cellular Therapies, United... 
Via Benzinga
News headline image
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results ↗
Axsome's AXS-05 met endpoints in Alzheimer's agitation studies, showing long-term safety and tolerability. FDA filing planned for late 2025. 
Via Benzinga
News headline image
Intra-Cellular Therapies' Treatment Reduces Schizophrenia Relapse Risk 63% ↗
Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk reduction and favorable safety profile. 
Via Benzinga
News headline image
Where Intra-Cellular Therapies Stands With Analysts ↗
 
Via Benzinga
News headline image
This Robinhood Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday ↗
 
Via Benzinga
News headline image
Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains' ↗
Acadia led a biotech selloff on Wednesday as Daybue sales missed expectations. 
Via Investor's Business Daily
Topics Earnings
News headline image
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves... 
Via PressReach
News headline image
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
China's Bilibili And Ollie's Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio? ↗
Top performing mid-cap stocks last week: BILI (+23%), IBRX (+22%), SSL (+20%), OLLI (+15%), ITCI (+13%), AMKR (+12%), IRTC (+11%), RKLB (+11%), BFH (+10%), BRFS (+10%). 
Via Benzinga
News headline image
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87 ↗
Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
News headline image
Patterson Companies, Silk Road Medical, Micron, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study ↗
Intra-Cellular Therapies reports positive topline results for Study 502 on lumateperone 42 mg as adjunctive therapy for major depressive disorder. FDA application expected in H2 2024. 
Via Benzinga
News headline image
Intra-Cellular Therapies Eyes $1.7 Billion Opportunity After Phase 3 Win ↗
The company hopes to expand its antipsychotic drug to depression treatment. 
Via Investor's Business Daily
News headline image
The Secret Stock Stash: 3 Overlooked Picks That Belong in Every Portfolio ↗
While it’s comforting to pick the ideas of the masses, these overlooked stocks may offer superior upside potential for the daring. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.